{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:58:40Z","timestamp":1791568720553,"version":"4.3.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Glioblastoma multiforme (GBM) is the most common and most aggressive primary tumor of the brain. After initial therapy and total resection of GBM, 80% to 90% of recurrences occur at the surgical margins. Currently, limited data are available in the literature on the possible use of <jats:sup>68<\/jats:sup>Ga\u2013prostate-specific membrane antigen (PSMA-11) for diagnosis of recurrence in GBM patients. The aim was to assess the feasibility and potential of <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT as a diagnostic procedure in patients with histologically confirmed of GBM and suspected recurrent disease on MRI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>No radiopharmaceutical-related adverse events were noted. Characterization of recurrent disease with MRI included T2-weighted fast spin-echo images, fluid-attenuated inversion recovery and diffusion-weighted imaging sequences, and gadolinium enhanced T1-weighted images. Visual interpretation of PET showed increased accumulation of <jats:sup>68<\/jats:sup>Ga-PSMA-11 in recurrent lesion detected by T1 contrast enhanced and diffusion-weighted imaging images in all patients with a median SUVmax of the tumor of 6.5 and an SUVmean of 3.5. The median tumor-to-background brain ratio and tumor-to-liver ratio obtained from <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT were 96.7 and 0.8, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The extremely low background uptake in normal brain tissue and consequently high tumor-to-brain ratio make <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT highly promising for diagnosis of recurrent disease in GBM patients. Although PSMA expression in recurrent GBM also opens a potential way for targeted peptide therapy with \u03b1\/\u03b2-emitters as well as for prediction of treatment with antiangiogenic agents, the low tumor-to-liver ratio observed in the majority of patients in this study suggests a limited role of radiolabeled PSMA ligands for targeted radionuclide therapy of recurrent GBM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002806","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T10:20:31Z","timestamp":1572430831000},"page":"11-18","source":"Crossref","is-referenced-by-count":65,"title":["68Ga\u2013Prostate-Specific Membrane Antigen-11 PET\/CT"],"prefix":"10.1097","volume":"45","author":[{"given":"Jolanta","family":"Kunikowska","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, Medical University of Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Kuli\u0144ski","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Medical University of Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoff","family":"Muylle","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Brussels\/UZ Brussel (VUB), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Koziara","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Maria Sk\u0142odowska-Curie Memorial Cancer Center and Institute, Warsaw, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kr\u00f3licki","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Medical University of Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"bib1-20230928","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.15252\/emmm.201302627","article-title":"Emerging treatment strategies for glioblastoma multiforme","volume":"6","year":"2014","journal-title":"EMBO Mol Med"},{"key":"bib2-20230928","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/00004647-199805000-00005","article-title":"\u201cFacilitated\u201d amino acid transport is upregulated in brain tumors","volume":"18","year":"1998","journal-title":"J Cereb Blood Flow Metab"},{"key":"bib3-20230928","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00259-007-0679-8","article-title":"The role of 18F-FLT in cancer imaging: does it really reflect proliferation?","volume":"35","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20230928","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","article-title":"Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme","volume":"135","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"bib5-20230928","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00259-015-3297-x","article-title":"Ga-68-PSMA PET\/CT imaging in primary hepatocellular carcinoma","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20230928","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1097\/RLU.0000000000001769","article-title":"Prostate-specific membrane antigen-targeted imaging with [18F]DCFPyL in high-grade gliomas","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib7-20230928","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00259-018-3934-2","article-title":"Glioblastoma multiforme: another potential application for 68Ga-PSMA PET\/CT as a guide for targeted therapy","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib8-20230928","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/RLU.0000000000001451","article-title":"Diagnostic value of 68Ga PSMA-11 PET\/CT imaging of brain tumors\u2014preliminary analysis","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib9-20230928","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11060-018-2825-5","article-title":"Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody","volume":"138","year":"2018","journal-title":"J Neurooncol"},{"key":"bib10-20230928","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1097\/RLU.0000000000002175","article-title":"Utility of 68Ga-PSMA-11 PET\/CT in imaging of glioma\u2014a pilot study","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib11-20230928","article-title":"18F-PSMA 1007 brain PET\/CT imaging in glioma recurrence","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib12-20230928","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","year":"2009","journal-title":"Lancet Oncol"},{"key":"bib13-20230928","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases","volume":"14","year":"2014","journal-title":"Cancer Cell Int"},{"key":"bib14-20230928","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00259-014-2766-y","article-title":"(68)Ga-PSMA PET\/CT imaging of metastatic clear cell renal cell carcinoma","volume":"41","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib15-20230928","doi-asserted-by":"crossref","first-page":"45","DOI":"10.30699\/ijp.13.1.45","article-title":"Expression of prostate-specific membrane antigen (PSMA) in brain glioma and its correlation with tumor grade","volume":"13","year":"2018","journal-title":"Iran J Pathol"},{"key":"bib16-20230928","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2967\/jnumed.111.096859","article-title":"Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis","volume":"53","year":"2012","journal-title":"J Nucl Med"},{"key":"bib17-20230928","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s00259-004-1590-1","article-title":"Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma","volume":"31","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib18-20230928","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/RLU.0000000000002398","article-title":"Hybrid 11C-MET PET\/MRI combined with \u201cmachine learning\u201d in glioma diagnosis according to the Revised Glioma WHO Classification 2016","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib19-20230928","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00259-007-0534-y","article-title":"FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumor grading","volume":"34","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib20-20230928","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1097\/RLU.0000000000002520","article-title":"Differential uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in low-grade versus high-grade gliomas in treatment-naive patients","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib21-20230928","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1097\/RLU.0000000000002280","article-title":"Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in cerebral radionecrosis: implications for diagnostic imaging of high-grade gliomas","volume":"43","year":"2018","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T03:45:48Z","timestamp":1695872748000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002806"}},"subtitle":["A New Imaging Option for Recurrent Glioblastoma Multiforme?"],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002806","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,29]]}}}